Symbicort in Chronic Obstructive Pulmonary Disease - Full Text View

Symbicort in Chronic Obstructive Pulmonary Disease (SYMBOL)

This study has been completed.

First Received on January 29, 2008. Last Updated on January 27, 2011 History of Changes

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00611520

Purpose

Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e. pneumologists and internists) are asked to document relevant data related to the budesonide/formoterole therapy in patients with COPD.

Condition
Chronic Obstructive Pulmonary Disease

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Symbicort in Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:

MedlinePlus related topics: COPD (Chronic Obstructive Pulmonary Disease)

Drug Information available for: Symbicort

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Secondary Outcome Measures:

to get further insight into the details of the use , dosage scheme and duration of treatment with budesonide /formoterol in this population

Enrollment:	64730
Study Start Date:	September 2005
Primary Completion Date:	December 2005 (Final data collection date for primary outcome measure)

Groups/Cohorts
1 Patients with COPD treated with budesonide/formoterol

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

patients

Criteria

Inclusion Criteria:

Patients with COPD treated with budesonide/formoterol

Exclusion Criteria:

limitations; possible risks; warnings; contraindications mentioned in the SPC.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00611520

Sponsors and Collaborators

AstraZeneca

Investigators

Study Chair:

Kai Richter, MD

Medical Department AstraZeneca Germany

More Information

No publications provided

Responsible Party:	Dr Kai Richter, AstraZeneca Germany
ClinicalTrials.gov Identifier:	NCT00611520 History of Changes
Other Study ID Numbers:	1312005009
Study First Received:	January 29, 2008
Last Updated:	January 27, 2011
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by AstraZeneca:

treatment of COPD
related to the budesonide/formoterole therapy in patients with COPD.

Additional relevant MeSH terms:

Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Respiratory Tract Diseases

Symbicort
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 09, 2012